Global Prenatal Testing Market Analysis & Forecast, 2016-2022

  • ID: 3894156
  • Report
  • Region: Global
  • 177 pages
  • BIS Research
1 of 6
Global Prenatal Market to Grow Over $7.28 Billion By 2022

FEATURED COMPANIES

  • Affymetrix, Inc.
  • Annoroad Diagnostics
  • Berry Genomics
  • CombiMatrix
  • LabCorp of America
  • Progenity
  • MORE
With the emergence of advanced technologies such as next generation sequencing, high throughput screening (HTS), and cell free fetal DNA, there has been a rise in the overall demand of the newly developed prenatal testing. Presently, the government bodies are focused mainly towards development of non-invasive solutions, launching a large number of screening programs, controlling the increasing cases of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients.

Governmental regulations and standards are playing a major role in sustaining the growth and development of the market. The main aim of these regulations is to make prenatal tests and solutions more adaptable and focused towards effective diagnosis of various genetic disorders & chromosomal abnormalities. The patients benefit indirectly through these regulations as it helps them save time and cuts-down the overall cost as the patients receive accurate and proper testing and diagnosis of the disease.

This study includes an overview and analysis of the prenatal testing market, by type of tests, techniques, and geographical regions, allowing the research to develop a comprehensive outlook of the market. The prenatal testing market report presents a detailed analysis of market dynamics and provides an extensive insight into the various forms of development, trends, and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW) and further subdivided into major countries of each region. For report coverage and primaries, we have contacted industry experts and consultants in countries like U.S., U.K., Spain, China, India, Germany, Spain, France and Italy among others.

The answers to the following key questions can be found in the report:
-  What are the major market drivers, challenges and opportunities of the prenatal testing market and their use cases?
-  What are the key trends and developments in the prenatal testing market for genetic disease management?
-  What are the key developmental strategies in different applications across all regions?
-  What are the different types of prenatal tests and the latest technologies entering the market?
-  How will the key market players leverage on key developments such as mergers and acquisitions, partnerships, and product launches among others?
-  Which geographical region will lead the global prenatal testing market by the end of the forecast period?
-  Who are the key players in the global prenatal testing market?
-  What are the key government regulations for different prenatal tests and techniques?
-  What are the recent key market trends and key developments in different geographical regions?
-  What types of non-invasive and invasive prenatal screening tests are performed during a pregnancy?
-  What is the global and regional market for prenatal tests, through forecast period?
-  What is the global and regional market for NIPTs through 2022?
-  What is the status of prenatal testing in developed, developing and other countries?

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, as well as their involvement in the prenatal testing market. The research incorporates Porter’s five force model for an in-depth analysis of the prenatal testing market and an assessment of the factors governing the same. The analysis builds on a well-compiled value chain, giving a detailed understanding of the ecosystem players and their rate of market penetration.

The report includes the profiles of major players in the prenatal testing market that allows the readers to gain an insight into the various industry trends.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Affymetrix, Inc.
  • Annoroad Diagnostics
  • Berry Genomics
  • CombiMatrix
  • LabCorp of America
  • Progenity
  • MORE
Executive Summary

1 Research Scope and Methodology
1.1 Scope of the Report
1.2 Global Prenatal Testing Market Research Methodology
1.2.1 Primary Data Sources
1.2.2 Secondary Data Sources

2 Introduction to the Prenatal Testing Market

3 Market Dynamics
3.1 Market Drivers
3.1.1 Emphasis on Early Detection and Prevention
3.1.2 Increasing Genetic and Congenital Disorders
3.1.3 Availability of Advanced Diagnosis and Screening Technologies
3.1.4 Evolving Government Initiatives
3.1.5 Adoption by Physicians: Incorporation of Tests into Clinical Care
3.1.6 Shifting of Reimbursement Policies towards more Genetics Coverage
3.2 Market Challenges
3.2.1 Risk of Ethical Issues and Social Stigma
3.2.2 Lack of Awareness among Consumers
3.2.3 High Cost of Screening and Diagnosis along with the Lack of Accuracy
3.3 Market Opportunities
3.3.1 Availability of Direct to Consumer Tests
3.3.2 Focus toward Pre-Implantation Genetic Diagnosis

4 Competitive Insights
4.1 Key Market Developments & Strategies
4.1.1 New Product Launch, Development and Expansion
4.1.2 Acquisitions, Partnerships and Collaborations
4.1.3 Business Expansion and Others
4.2 Industry Attractiveness

5 Industry Analysis
5.1 Patent Analysis
5.2 Consortiums, Alliances and Regulatory Bodies
5.3 Value Chain Analysis

6 Global Prenatal Testing Market, Analysis & Forecast
6.1 Assumptions & Limitations for Analysis and Forecast of the Global Prenatal Testing Market
6.2 Market Overview
6.3 Global Prenatal Testing Market by Screening Methods
6.3.1 Non-Invasive Prenatal Tests (NIPT)
6.3.1.1 NIPT Market by Geography
6.3.1.2 North America NIPT Market
6.3.1.2.1 Market Share Analysis by Countries
6.3.1.2.1.1 The U.S.
6.3.1.2.1.2 Canada
6.3.1.2.1.3 Mexico
6.3.1.3 Europe NIPT Market
6.3.1.3.1 Market Share Analysis by Countries
6.3.1.3.1.1 Germany
6.3.1.3.1.2 France
6.3.1.3.1.3 Italy
6.3.1.3.1.4 U.K.
6.3.1.3.1.5 Spain
6.3.1.3.1.6 Other European Countries
6.3.1.4 APAC NIPT Market:
6.3.1.4.1 Market Share Analysis by Countries
6.3.1.4.1.1 China
6.3.1.4.1.2 India
6.3.1.4.1.3 Japan
6.3.1.4.1.4 Other APAC Countries
6.3.1.5 Rest of the World NIPT Market
6.3.2 Other Prenatal Screening Tests
6.3.2.1 Cell-Free Fetal DNA Test
6.3.2.2 Maternal Serum Screening (MSS)
6.3.2.3 Nuchal Scan (NT Procedure)
6.3.2.4 Triple Test
6.3.2.5 Quadruple Test
6.4 Global Prenatal Testing Market by Diagnosis Methods
6.4.1 Global Prenatal Diagnosis Market by Test Type
6.4.1.1 Non-Invasive Prenatal Diagnosis Market
6.4.1.1.1 Ultrasonography
6.4.1.1.2 Fetal Cells in Maternal Blood (FCMB)
6.4.1.1.3 Pre-Implantation Genetic Diagnosis
6.4.1.2 Invasive Prenatal Diagnosis Market
6.4.1.2.1 Invasive Test Market by Test Types
6.4.1.2.1.1 Amniocentesis
6.4.1.2.1.2 Chorionic Villus Sampling (CVS)
6.4.1.2.1.3 Other Invasive Tests
6.4.1.2.1.3.1 Fetal Blood Sampling (FBS)
6.4.1.2.1.3.2 Transcervical Retrieval of Trophoblast Cells
6.4.1.2.1.3.3 Embryoscopy and Fetoscopy
6.4.1.2.2 Invasive Test Market by Geography
6.4.1.2.2.1 North America Invasive Test Market
6.4.1.2.2.1.1 Market Share Analysis by Countries
6.4.1.2.2.1.1.1 The U.S.
6.4.1.2.2.1.1.2 Canada
6.4.1.2.2.1.1.3 Mexico
6.4.1.2.2.2 Europe Invasive Test Market
6.4.1.2.2.2.1 Market Share Analysis by Countries
6.4.1.2.2.2.1.1 Germany
6.4.1.2.2.2.1.2 France
6.4.1.2.2.2.1.3 Italy
6.4.1.2.2.2.1.4 U.K.
6.4.1.2.2.2.1.5 Spain
6.4.1.2.2.2.1.6 Other European Countries
6.4.1.2.2.3 APAC Invasive Test Market
6.4.1.2.2.3.1 Market Share Analysis by Countries
6.4.1.2.2.3.1.1 China
6.4.1.2.2.3.1.2 India
6.4.1.2.2.3.1.3 Japan
6.4.1.2.2.3.1.4 Other APAC Countries
6.4.1.2.2.4 Rest of the World Invasive Test Market
6.4.2 Global Prenatal Diagnosis Market by Geography
6.4.2.1 North America
6.4.2.1.1 Market Analysis by Country
6.4.2.2 Europe
6.4.2.2.1 Market Analysis by Country
6.4.2.3 APAC
6.4.2.3.1 Market Analysis by Country
6.4.2.4 Rest of the World (RoW)

7 Company Profiles
7.1 Agilent Technologies
7.1.1 Overview
7.1.2 Financials
7.1.2.1 Financial Summary
7.1.3 SWOT Analysis
7.2 CombiMatrix
7.2.1 Overview
7.2.2 Financials
7.2.2.1 Financial Summary
7.2.3 SWOT Analysis
7.3 Illumina Inc.
7.3.1 Overview
7.3.2 Financials
7.3.2.1 Financial Summary
7.3.3 SWOT Analysis
7.4 LabCorp of America
7.4.1 Overview
7.4.2 Financials
7.4.2.1 Financial Summary
7.4.3 SWOT Analysis
7.5 Natera Inc.
7.5.1 Overview
7.5.2 Financials
7.5.2.1 Financial Summary
7.5.3 SWOT Analysis
7.6 Quest Diagnostics
7.6.1 Overview
7.6.2 Financials
7.6.2.1 Financial Summary
7.6.3 SWOT Analysis
7.7 Roche Holding
7.7.1 Overview
7.7.2 Ariosa Diagnostics
7.7.2.1 Overview
7.7.3 Financials
7.7.3.1 Financial Summary
7.7.4 SWOT Analysis
7.8 Sequenom Inc.
7.8.1 Overview
7.8.2 Financials
7.8.2.1 Financial Summary
7.8.3 SWOT Analysis
7.9 Snapshot of Some Players
7.9.1 Affymetrix, Inc.
7.9.2 Annoroad Diagnostics
7.9.3 Berry Genomics
7.9.4 BGI Diagnostics
7.9.5 Progenity
7.10 List of Other Prominent Players

List of Tables
Table 2.1 Types of Genetic Diseases in Fetuses: An Overview
Table 2.2 Prenatal Testing: Key Technologies
Table 3.1 Live Birth Rate- Risk of Genetic Abnormality/Disorders by Maternal Age
Table 3.2 Average Cost of Non-Invasive Prenatal Test (NIPT)
Table 4.1 New Product Launch, Development and Expansion
Table 4.2 Recent Acquisitions, Partnerships and Collaborations
Table 4.3 Recent Business Expansion and Others
Table 4.4 Key Factors Considered for Threat of New Entrants: Prenatal Testing
Table 4.5 Key Factors Affecting Bargaining Power of Buyers: Prenatal Testing
Table 4.6 Key Factors Affecting the Bargaining Power of Suppliers: Prenatal Testing
Table 4.7 Key Factors Affecting Threat of Substitute Products: Prenatal Testing
Table 4.8 Key Factors Determining Rivalry among Existing Firms: Prenatal Testing
Table 5.1 Example of Some Recent Patents
Table 5.2 Example of Some Regulatory Bodies/Associations/Consortium
Table 6.1 Global Prenatal Screening Market Size, by Test Type, 2015-2022,
Table 6.2 Geographical Analysis of Players and Cost of NIPT
Table 6.3 Global NIPT Screening Market Size, by Geography, 2015-2022,
Table 6.4 NIPT: Recent Key Developments
Table 6.5 Amniocentesis Prenatal Testing Method Snapshot
Table 6.6 North America Prenatal Diagnosis Market Scope Statistics
Table 6.7 North America: Prenatal Diagnosis Market, by Test Type, 2015-2022
Table 6.8 Recent Key Developments in North America
Table 6.9 Europe Prenatal Diagnosis Market Scope Stats
Table 6.10 Europe: Prenatal Diagnosis Market, by Test Type, 2015-2022
Table 6.11 APAC Prenatal Diagnosis Market Scope Stats
Table 6.12 APAC: Prenatal Diagnosis Market, by Test Type, 2015-2022
Table 6.13 Recent Key Developments in APAC
Table 6.14 RoW: Prenatal Diagnosis Market, by Test Type, 2015-2022
Table 6.15 RoW Prenatal Diagnosis Market Scope Stats
Table 7.1 Snapshot of Other Key Players
Table 7.2 List of other Prominent Players
List of Figures
Figure 1 Global Prenatal Testing Market Size, 2015-2022 ($Billion)
Figure 2 Global Prenatal Testing Market Size, by Type, 2015-2022 ($billion)
Figure 3 Global Prenatal Diagnosis Market, by Geography, 2015 and 2022 ($Billion)
Figure 1.1 Global Prenatal Testing Market Scope
Figure 1.2 Research Methodology
Figure 2.1 Prenatal Testing: Key Elements Covered
Figure 2.2 History & Evaluation of Prenatal Testing
Figure 2.3 Prenatal Testing Timeline during Pregnancy (Till Second Trimester)
Figure 2.4 Factors Responsible for Prenatal Testing
Figure 3.1 Market Dynamics for Prenatal Testing
Figure 3.2 Prenatal Testing Market: Key Market Drivers
Figure 3.3 Prenatal Testing: Key Challenges
Figure 3.4 Prenatal Testing: Key Opportunities
Figure 4.1 Recent Market Development Strategy Snapshot Analysis
Figure 4.2 Key Market Developments & Strategies
Figure 4.3 Porter’s Five Forces Analysis
Figure 5.1 Value Chain Analysis
Figure 6.1 Classification of Global Prenatal Testing Market
Figure 6.2 Global Prenatal Testing Market: Opportunity Matrix
Figure 6.3 Global Prenatal Testing Market, by Technique 2015-2022 ($Billion)
Figure 6.4 Example of a Screening Method
Figure 6.5 Global Prenatal Screening Market Size, 2015-2022, ($Billion)
Figure 6.6 Prenatal Screening Methods
Figure 6.7 NIPT Pricing and Market Penetration Analysis
Figure 6.8 NIPT Pricing and Market Size
Figure 6.9 North America: NIPT Market by Countries, 2015-2022 ($Million)
Figure 6.10 The U.S. NIPT Market, 2015-2022 ($Million)
Figure 6.11 Canada NIPT Market, 2015-2022 ($Million)
Figure 6.12 Mexico NIPT Market, 2015-2022 ($Million)
Figure 6.13 Europe: NIPT Market by Countries, 2015-2022 ($Million)
Figure 6.14 Germany NIPT Market, 2015-2022 ($Million)
Figure 6.15 France NIPT Market, 2015-2022 ($Million)
Figure 6.16 Italy NIPT Market, 2015-2022 ($Million)
Figure 6.17 U.K. NIPT Market, 2015-2022 ($Million)
Figure 6.18 Spain NIPT Market, 2015-2022 ($Million)
Figure 6.19 Other European Countries NIPT Market, 2015-2022 ($Million)
Figure 6.20 APAC: NIPT Market by Countries, 2015-2022 ($Million)
Figure 6.21 China NIPT Market, 2015-2022 ($Million)
Figure 6.22 Indian NIPT Market, 2015-2022 ($Million)
Figure 6.23 Japan NIPT Market, 2015-2022 ($Million)
Figure 6.24 Other APAC Countries NIPT Market, 2015-2022 ($Million)
Figure 6.25 ROW NIPT Market, 2015-2022 ($Million)
Figure 6.26 Global Others Screening Test Market, 2015-2022 ($Billion)
Figure 6.27 Factors Responsible for Cell-Free Fatal DNA
Figure 6.28 Cell-Free Fatal DNA Test; Suggested Time for Testing
Figure 6.29 Prenatal Diagnosis Benefits
Figure 6.30 Global Prenatal Diagnosis Market Size, 2015-2022, ($Billion)
Figure 6.31 Prenatal Diagnosis Market by Test Type
Figure 6.32 Global Prenatal Diagnosis Market Share, by Test Type, 2015
Figure 6.33 Global Non-Invasive Prenatal Diagnosis Market, 2015-2022 ($Million)
Figure 6.34 Global Invasive Prenatal Diagnosis Test Market, by Test type, 2015-2022 ($Million)
Figure 6.35 Amniocentesis Schematic Diagram
Figure 6.36 Types of procedure for CVS
Figure 6.37 Types of Chorionic Villus Sampling (CVS) Procedure
Figure 6.38 Methods of Transcervical Cell collection
Figure 6.39 Global Invasive Prenatal Diagnosis Test Market, by Geography, 2015-2022 ($Million)
Figure 6.40 North America: Invasive test Market by Countries, 2015-2022 ($Million)
Figure 6.41 The U.S. Invasive Test Market, 2015-2022 ($Million)
Figure 6.42 Canada Invasive Test Market, 2015-2022 ($Million)
Figure 6.43 Mexico Invasive Test Market, 2015-2022 ($Million)
Figure 6.44 Europe: Invasive Test Market by Countries, 2015-2022 ($Million)
Figure 6.45 Germany Invasive Test Market, 2015-2022 ($Million)
Figure 6.46 France Invasive Test Market, 2015-2022 ($Million)
Figure 6.47 Italy Invasive Test Market, 2015-2022 ($Million)
Figure 6.48 U.K. Invasive Test Market, 2015-2022 ($Million)
Figure 6.49 Spain Invasive Test Market, 2015-2022 ($Million)
Figure 6.50 Other European Countries Invasive Test Market, 2015-2022 ($Million)
Figure 6.51 APAC: Invasive Test Market by Countries, 2015-2022 ($Million)
Figure 6.52 China Invasive Test Market, 2015-2022 ($Million)
Figure 6.53 India Invasive Test Market, 2015-2022 ($Million)
Figure 6.54 Japan Invasive Test Market, 2015-2022 ($Million)
Figure 6.55 Other APAC Countries Invasive Test Market, 2015-2022 ($Million)
Figure 6.56 ROW Invasive Test Market, 2015-2022 ($Million)
Figure 6.57 Global Prenatal Diagnosis Market by Geography
Figure 6.58 Global Prenatal Diagnosis Market, by Geography, 2015-2022 ($Million)
Figure 6.59 North American Market Dynamics
Figure 6.60 Key Players in North American Prenatal Testing Market
Figure 6.61 Key Factors Driving the Prenatal Testing Market in Europe
Figure 6.62 Key Players in European Prenatal Testing Market
Figure 6.63 Key Factors Driving the Prenatal Testing Market in APAC
Figure 6.64 Challenges for Prenatal Testing in APAC
Figure 6.65 Key Players in APAC Prenatal Testing Market
Figure 6.66 Key Factors Driving the Prenatal Testing Market in Row
Figure 6.67 Key Players in RoW Prenatal Testing Market
Figure 7.1 Agilent: Overall Financials, 2013-2015
Figure 7.2 Agilent: Net Revenue by Business Segment, 2013-2015
Figure 7.3 Agilent: Revenue across Different Geographies, 2013-2015
Figure 7.4 Agilent: SWOT Analysis
Figure 7.5 CombiMatrix: Overall Financials, 2013-2015
Figure 7.6 CombiMatrix: SWOT Analysis
Figure 7.7 Illumina: Overall Financials, 2013-2015
Figure 7.8 Illumina: Net Revenue by Business Segment, 2013-2015
Figure 7.9 Illumina: Revenue across Different Geographies, 2013-2015
Figure 7.10 Illumina: SWOT Analysis
Figure 7.11 LabCorp: Overall Financials, 2013-2015
Figure 7.12 LabCorp: Net Revenue by Business Segment, 2013-2015
Figure 7.13 LABCORP: SWOT Analysis
Figure 7.14 Natera Inc.: Overall Financials, 2013-2015
Figure 7.15 Natera Inc.: Revenue across Different Geographies, 2013-2015
Figure 7.16 Natera Inc.: SWOT Analysis
Figure 7.17 Quest Diagnostics: Overall Financials, 2013-2015
Figure 7.18 Quest Diagnostics: Net Revenue by Business Segments, 2013-2015
Figure 7.19 Quest Diagnostics: SWOT Analysis
Figure 7.20 Roche Holding: Overall Financials, 2013-2015
Figure 7.21 Roche Holding: Net Revenue by Business Segments, 2013-2015
Figure 7.22 Roche Holding: Revenue across Different Geographies, 2013-2015
Figure 7.23 Roche Holding: SWOT Analysis
Figure 7.24 Sequenom Inc.: Overall Financials, 2013-2015
Figure 7.25 Sequenom Inc.: Net Revenue by Business Segments, 2013-2015
Figure 7.26 Sequenom Inc.: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Affymetrix, Inc.
  • Annoroad Diagnostics
  • Berry Genomics
  • CombiMatrix
  • LabCorp of America
  • Progenity
  • MORE
Prenatal testing is a series of preventive measure tests performed on expectant mothers to screen and diagnose genetic disorder in fetuses through gene mapping and sequencing. Prenatal testing is a series of preventive measure tests performed on expectant mothers to screen and diagnose genetic disorder in fetuses through gene mapping and sequencing of fetal cells. There are various factors that contribute towards the growth of the market for prenatal testing, such as: advanced maternal age, previous child with a chromosome abnormality, family history of chromosome abnormality, family history of single gene disorders, family history of neural tube defect and congenital structural abnormalities, abnormalities identified  during pregnancy among others.

New technologies such as NGS, PCR, FISH, microarray, aCGH and MSS among others are becoming popular in the prenatal diagnosis and screening market. Evolving government initiatives, adoption by physicians, incorporation of tests into clinical care and allocation of reimbursement policies towards more genetic testing coverage are some of the major reasons which are driving the market. High pricing of screening and diagnostic tests along with the risk of accuracy causes hindrances in the growth of the market. In developing countries, most of the people do not have sufficient monetary resources for undergoing these expensive tests.

Recent acquisitions of Vanadis Diagnostics (a Swedish company, working on developing a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA) by PerkinElmer has opened up new opportunities for new start-ups which are working in the research and development sector  of the Prenatal testing market. Companies including PerkinElmer, VitroLife, Roche and many more are collaborating or acquiring or merging with small time players to gain a bigger market share and merging existing technology with advanced processes created by these newbie’s for better market growth. A market study by BIS Research, titled, Global Prenatal Market – Analysis & Forecast, 2016-2022 has acknowledged the implementation of the Prenatal Process in the world.

The market is foreseen to experience high market growth potential by the end of 2022 due to its steady adaptability and increasing rate of adoption. Moreover, the availability of high skilled personnel, skilful quality of testing at economical prices, and increasing awareness about the prenatal testing services are some of the major factors that are contributing to the growth of the prenatal market. Apart from these, availability of advanced diagnostic  and screening technologies and government initiatives in the prenatal field are enhancing the prenatal market in developing countries which provide treatment and other facilities at low cost. The non-invasive prenatal tests are becoming increasingly   popular and acquiring a lot of attention in the Prenatal Market because of its effectiveness and non-invasive nature. This technology can be seen as one of the foremost factors contributing to the future growth of the prenatal testing market.

The research study also incorporates Porter’s Five Forces Analysis to provide an in-depth analysis of the market. The report provides a substantial analysis of the major aspects of the industry including market drivers and opportunities, important prenatal procedures, various instruments, reagents and media used in the prenatal testing market.

Prenatal testing emphasizes on early detection and prevention of fetus abnormality, which is leading to a dynamic growth of the market. The numbers of screening and diagnostic tests are increasing rapidly and have reached around 3500 tests in 2016. Most of these tests are readily available to the common people and are used in developed countries where parents are more conscious about the drawbacks of genetic disorders and want to employ mediums of early detection of genetic disorders in their pre-born baby. On the other hand, in developing countries, in spite of the availability of a large number of tests, their clinical application is slow as compared to developed countries which can be foreseen as an opportunity for this sector. The report also includes profiles of major companies like Sequenom, Ariosa Diagnostics, Natera, Labcorp of America, Illumina Inc., in the market players section.

The global prenatal testing market is growing at a CAGR of 28.85% from 2016 to 2022 and is estimated to grow over $7.2 billion by 2022. Prenatal tests are classified into two main categories viz. Screening and Diagnostics. Both screening and diagnostics have witnessed an exponential growth in procuring treatments for disorders which increased in the past two decades. Screening prenatal tests are further divided into Non-Invasive Prenatal Testing Screening (NIPT) and other screening processes such as Cell-Free Foetal DNA (cffDNA), Maternal Serum Screening (MSS), Nuchal Scan (NT Procedure), Triple Test, and Quadruple Test.

The diagnostics market is further divided into two categories viz. Invasive and Non-Invasive. Invasive testing is a conventional technology amongst prenatal techniques because of which it is still leading the market. Due to low cost, invasive testing is preferred by people in developing countries, whereas the non-invasive is costly as well as comparatively a more recent technology which will take time to gain popularity. Non-invasive techniques cause no harm to the human body and thus are gaining preference amongst patients in developed regions around the world.

The U.S., the U.K., Japan, and India show a dynamic growth in the overall market due to an increasing prevalence of genetic disorders in these countries. The APAC region is focusing more on technological development and introduction of advanced tools in the field of prenatal and newborn care in order to develop specific tests and solutions.
Note: Product cover images may vary from those shown
5 of 6
- Affymetrix, Inc.
- Agilent Technologies
- Annoroad Diagnostics
- Ariosa Diagnostics
- BGI Diagnostics
- Berry Genomics
- CombiMatrix
- Illumina Inc.
- LabCorp of America
- Natera Inc.
- Progenity
- Quest Diagnostics
- Roche Holding
- Sequenom Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll